TRML241220C20000
- 3.89
- -4.40-53.08%
Tourmaline Bio Newsroom
Leerink Partners Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Strategic Developments in Tourmaline Bio's Cardiovascular Programs Drive Buy Rating
UBS Raises Price Target on Tourmaline Bio to CA$73 From CA$70, Maintains Neutral Rating
Tourmaline Bio Price Target Announced at $50.00/Share by BMO Capital
Tourmaline Bio Initiated at Outperform by BMO Capital
Tourmaline Bio Analyst Ratings
BMO Capital Initiates Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $50
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Guggenheim Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald Initiates Tourmaline Bio(TRML.US) With Buy Rating
Guggenheim Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating